Senior Medical Director, Global Medical AffairsSanofi, Cambridge, MA, USACambridge, Massachusetts, United States
OC 14.1 - Perioperative management with efanesoctocog alfa in adults, adolescents, and children with severe hemophilia A in the phase 3 XTEND clinical program
Sunday, June 23, 202409:30 – 09:45 ICT
OC 50.1 - First interim analysis of clinical outcomes in adults and adolescents with severe hemophilia A receiving efanesoctocog alfa prophylaxis in XTEND-ed, a phase 3 long-term extension study
Tuesday, June 25, 202409:30 – 09:45 ICT
